News >

Phase III Avelumab Trial Discontinued in Frontline Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Mar 20, 2019

The ongoing phase III JAVELIN Ovarian PARP 100 study (NCT03642132), which was evaluating the efficacy and safety of avelumab (Bavencio) in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib (Talzenna) in patients with locally advanced or metastatic ovarian cancer, has been discontinued, according to Merck KGaA and Pfizer, the companies that collaborated on the trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication